S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains

Fusion Pharmaceuticals (FUSN) Stock Forecast & Price Target

$21.24
-0.02 (-0.09%)
(As of 04/17/2024 ET)

Fusion Pharmaceuticals Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 14 Analyst Ratings

Analysts' Consensus Price Target

$20.25
-4.66% Downside
High Forecast$24.00
Average Forecast$20.25
Low Forecast$15.00
TypeCurrent Forecast
4/19/23 to 4/18/24
1 Month Ago
3/20/23 to 3/19/24
3 Months Ago
1/19/23 to 1/19/24
1 Year Ago
4/19/22 to 4/19/23
Consensus Rating
Hold
Hold
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
4 Buy rating(s)
8 Buy rating(s)
8 Buy rating(s)
Hold
13 Hold rating(s)
8 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$20.25$18.38$13.17$11.25
Predicted Upside-4.66% Downside35.38% Upside101.58% Upside234.32% Upside
Get Fusion Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for FUSN and its competitors with MarketBeat's FREE daily newsletter.

FUSN Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

FUSN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Fusion Pharmaceuticals Stock vs. The Competition

TypeFusion PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.07
2.68
2.49
Consensus RatingHoldModerate BuyHold
Predicted Upside-4.66% Downside923.17% Upside12.15% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/16/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold
3/20/2024Bloom Burton
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Martin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
3/20/2024B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Y. Zhi
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$13.00 ➝ $23.00+8.75%
3/20/2024Jonestrading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold
3/20/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Sector Perform$16.00 ➝ $21.00-0.85%
3/19/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
F. Khurshid
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
3/19/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold$11.00 ➝ $21.00-0.05%
3/19/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold$10.00 ➝ $21.00+0.05%
3/19/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingStrong-Buy ➝ Market Perform
3/19/2024Brookline Capital Management
Subscribe to MarketBeat All Access for the recommendation accuracy rating
K. Dolliver
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
3/19/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Hsieh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
3/19/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Nierengarten
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral$24.00+14.29%
3/19/2024SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Market Perform$17.00 ➝ $21.00+97.37%
1/5/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$13.00 ➝ $15.00+77.94%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 03:06 AM ET.

FUSN Price Target - Frequently Asked Questions

What is Fusion Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 14 analysts in the last year, the consensus rating for Fusion Pharmaceuticals stock is Hold based on the current 13 hold ratings and 1 buy rating for FUSN. The average twelve-month price prediction for Fusion Pharmaceuticals is $20.25 with a high price target of $24.00 and a low price target of $15.00. Learn more on FUSN's analyst rating history.

Do Wall Street analysts like Fusion Pharmaceuticals more than its competitors?

Analysts like Fusion Pharmaceuticals less than other Medical companies. The consensus rating for Fusion Pharmaceuticals is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how FUSN compares to other companies.

Is Fusion Pharmaceuticals being downgraded by Wall Street analysts?

Over the previous 90 days, Fusion Pharmaceuticals's stock had 6 downgrades by analysts.

Does Fusion Pharmaceuticals's stock price have much upside?

According to analysts, Fusion Pharmaceuticals's stock has a predicted upside of 18.08% based on their 12-month stock forecasts.

What analysts cover Fusion Pharmaceuticals?

Stock Ratings Reports and Tools

This page (NASDAQ:FUSN) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners